Vivo Capital Lowers stake in Sagent Pharmaceuticals Inc (SGNT)

Sagent Pharmaceuticals Inc (SGNT) : Vivo Capital reduced its stake in Sagent Pharmaceuticals Inc by 0.07% during the most recent quarter end. The investment management company now holds a total of 6,495,416 shares of Sagent Pharmaceuticals Inc which is valued at $141,145,390 after selling 4,321 shares in Sagent Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Sagent Pharmaceuticals Inc makes up approximately 33.87% of Vivo Capital’s portfolio.

Other Hedge Funds, Including , Pura Vida Investments sold out all of its stake in SGNT during the most recent quarter. The investment firm sold 89,713 shares of SGNT which is valued $1,949,463. Piermont Capital Management sold out all of its stake in SGNT during the most recent quarter. The investment firm sold 116,005 shares of SGNT which is valued $2,520,789.Raymond James Financial Services Advisors boosted its stake in SGNT in the latest quarter, The investment management firm added 28,207 additional shares and now holds a total of 66,411 shares of Sagent Pharmaceuticals Inc which is valued at $1,443,111. Sagent Pharmaceuticals Inc makes up approx 0.01% of Raymond James Financial Services Advisors’s portfolio.Raymond James Associates boosted its stake in SGNT in the latest quarter, The investment management firm added 36,872 additional shares and now holds a total of 184,747 shares of Sagent Pharmaceuticals Inc which is valued at $4,014,552. Sagent Pharmaceuticals Inc makes up approx 0.01% of Raymond James Associates’s portfolio.Dekabank Deutsche Girozentrale boosted its stake in SGNT in the latest quarter, The investment management firm added 5,400 additional shares and now holds a total of 19,500 shares of Sagent Pharmaceuticals Inc which is valued at $422,565.

On the company’s financial health, Sagent Pharmaceuticals Inc reported $0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.00. The company had revenue of $67.80 million for the quarter, compared to analysts expectations of $74.22 million. The company’s revenue was down -17.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.04 EPS.

Many Wall Street Analysts have commented on Sagent Pharmaceuticals Inc. Sagent Pharmaceuticals Inc was Downgraded by Piper Jaffray to ” Neutral” on Jul 11, 2016. Sagent Pharmaceuticals Inc was Downgraded by Raymond James to ” Mkt Perform” on Jul 11, 2016.

Sagent Pharmaceuticals Inc. (Sagent) formerly Sagent Holding Co. is an injectable pharmaceutical company that develops and sources products that the Company sells primarily in the United States. Sagent focuses primarily on generic injectable pharmaceuticals. Sagent offers its customers a range of products across anti-infective oncolytic and critical care indications in a variety of presentations including single- and multi-dose vials pre-filled ready-to-use syringes medical devices and premix bags. As of October 31 2010 Sagent marketed 21 products. The Company has a 50/50 joint venture known as Sagent Strides LLC (Sagent Strides) with a subsidiary of Strides Arcolab Limited (Strides) which is an Indian manufacturer of finished pharmaceutical products.

Leave a Reply

Sagent Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sagent Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.